Literature DB >> 6141409

Cyclosporin for acute dermatomyositis.

P Zabel, G Leimenstoll, W L Gross.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6141409     DOI: 10.1016/s0140-6736(84)90391-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

Review 1.  Emerging indications for the use of cyclosporin in organ transplantation and autoimmunity.

Authors:  P A Keown
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 2.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 3.  Polymyositis/dermatomyositis: the current position.

Authors:  A Urbano-Márquez; J Casademont; J M Grau
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

4.  Polymyositis and cyclosporin A.

Authors:  J Alijotas; J Barquinero; J Ordi; M Vilardell
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

5.  Cyclosporin for polymyositis.

Authors:  S van der Meer; J W Imhof; J C Borleffs
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

6.  Severe dermatomyositis treated with cyclosporin A.

Authors:  L Ejstrup
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

Review 7.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Cyclosporin in the management of polymyositis and dermatomyositis.

Authors:  C J Lueck; P Trend; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-11       Impact factor: 10.154

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.